WTBA:NASDAQWest Bancorporation Analysis
Data as of 2026-05-11 - not real-time
$24.09
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
West Bancorporation posted a solid Q1 2026 earnings beat with net income of $10.6 million and EPS of $0.61, up from $7.4 million and $0.43 in the prior quarter, underscoring a 16.6% revenue growth trajectory. Its dividend yield of 4.15% and a payout ratio under 50% signal a sustainable income stream, while the price‑to‑earnings multiple of 11.6 sits well below the industry average of 16.4, indicating relative cheapness. Technically, the stock trades at $24.09, just above the 20‑day SMA (24.16) and 50‑day SMA (24.02) and comfortably above the 200‑day SMA (22.16), supporting a bullish bias, yet the MACD histogram remains negative and volume is on a downtrend, suggesting short‑term caution. The 30‑day volatility of 28% and a beta near 0.9 reflect heightened price swings typical for regional banks, but the current support at $23.41 and resistance at $25.13 provide a clear trading range. Overall, the combination of earnings momentum, attractive dividend, and valuation discount positions WTBA as a modest upside play pending confirmation of technical strength.
Looking ahead, the DCF‑derived fair value of roughly $53 implies significant long‑term upside, though the modest 6.9% upside/downside metric tempers expectations. The company’s strong cash position ($375 M) relative to debt ($385 M) and a low debt‑to‑equity ratio further mitigate financial risk. Investors should monitor volume trends and MACD signals for entry timing, while the fundamental backdrop remains supportive of a buy‑and‑hold approach.
Looking ahead, the DCF‑derived fair value of roughly $53 implies significant long‑term upside, though the modest 6.9% upside/downside metric tempers expectations. The company’s strong cash position ($375 M) relative to debt ($385 M) and a low debt‑to‑equity ratio further mitigate financial risk. Investors should monitor volume trends and MACD signals for entry timing, while the fundamental backdrop remains supportive of a buy‑and‑hold approach.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Recent earnings beat and dividend yield
- Negative MACD histogram and decreasing volume
- Price near established support level
Medium Term
1–3 yearsPositive
Model confidence: 7/10
Key Factors
- Valuation discount vs industry PE
- Revenue growth of 16.6% and improving EPS
- Potential upside toward resistance at $25.13
Long Term
> 3 yearsPositive
Model confidence: 8/10
Key Factors
- DCF fair value indicating substantial upside
- Sustainable dividend and strong cash position
- Undervalued price relative to long‑term fundamentals
Key Metrics & Analysis
Financial Health
Revenue Growth16.60%
Profit Margin35.62%
P/E Ratio11.6
ROE13.88%
ROA0.88%
P/B Ratio1.5
Op. Cash Flow$49.6M
Industry P/E16.4
Technical Analysis
TrendBullish
RSI49.8
Support$23.41
Resistance$25.13
MA 20$24.16
MA 50$24.02
MA 200$22.16
MACDBearish
VolumeDecreasing
Fear & Greed Index90.73
Valuation
Fair Value$53.40
Target Price$25.75
Upside/Downside6.89%
GradeUndervalued
TypeBlend
Dividend Yield4.15%
Risk Assessment
Beta0.92
Volatility28.31%
Sector RiskMedium
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.